



Vaccines and The National Vaccine Injury Compensation Program

Citation

Vaccines and The National Vaccine Injury Compensation Program (2000 Third Year Paper)

Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:9453695>

Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

**Vaccines and the
The National Vaccine Injury Compensation Program**

Katherine Davenport
Food and Drug Law
Third Year Written Work Requirement
Harvard Law School
April 10, 2000

Table of Contents

Introduction
2

I. The Food and Drug Administration: Regulation of Vaccines and Vaccine Manufacturers
5

A. History of the FDA Regulation of Vaccines and Vaccine Manufacturers
5

B. The Review of Biological Products
6

C. FDA Regulation of Vaccines and Vaccine Manufacturers
8

1. FDA Regulation and Licensing of Vaccine Manufacturers 9

2. FDA Regulation of Vaccines
11

3. FDA Regulation of Vaccine Labeling
12

4. FDA Monitoring of Adverse Events
12

D. Conclusion: Limited Effect of FDA Regulation
14

II. How Do We Confront the Adverse Effects of Vaccination?

One Alternative: The Civil Tort System
15

A. Theories of Liability
15

B. Failure of the Tort System
17

III.

The National Vaccine Injury Compensation Program **21**

A. The Design of the NVICP
22

1. Location of the NVICP in the Court of Federal Claims
22

2. The Special Masters	24
3. Petitioners Under the NVICP	25
4. The Vaccine Injury Table	27
a. Listed Vaccines	27
b. Burden of Proof	29
c. Revision of the Table	30
B. The NVICP Proceedings	32
1. Conduct of Proceedings	32
2. Petition Content	33
3. Experts	34
C.	

Compensation Recoverable	36
1. Financing of Compensation	36
2. Conventional Damages	37
3. Costs of Proceedings	38
a. Attorneys' Fees	38
b. Fees of Experts	41
4. Process for Appeals	42
D. Program Statistics	43
1. Petitions Filed	43
2. Adjudication	44
3. Awards	44

IV.

The Liability of Vaccine Manufacturers after the National Vaccine

Injury Compensation Program	45
A. NVICP Limitations on Manufacturer Liability	45
1. Unavoidable Side Effects	45
2. Statutory Presumption of Due Care in Packaging and Warning	47
3. Direct Warnings	48
4. Punitive Damages	51
B. Restriction on Evidence from the NVICP	51

V.

**Has the NVICP Achieved Its Goals? Proposals
for Reform 53**

A. First Goal: Protecting the Vaccine Supply and
Reducing Vaccine Litigation
53

B. Second Goal: Compensating Injured Vaccinees
55

 1. Length of NVICP Proceedings
56

 2. Adversarial Nature of Proceedings
58

 3. Loss of the Presumption of Vaccine Injury
60

C. Eradicating the Tension Between the Two Goals of the NVICP
62

D. Eradicating the Tension Between the NVICP and the
Safety Goal of the Vaccine Act
62

**Conclusion
65**